🧫
ASC antibody treatment in SH-SY5Y-APP695 cells
active
experiment
Created: 2026-04-10T22:44:55
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-dd3daa4a-cf5a-40b5-a70d-f5340240350e
🧫 Experiment Protocol
ExploratoryAlzheimer's diseaseASCSH-SY5Y-APP695 cellsproposed
This experiment investigated the effects of ASC neutralizing antibodies targeting different domains of the ASC protein on cell apoptosis and amyloid-β (Aβ) production in vitro. SH-SY5Y-APP695 cells, which are human neuroblastoma cells transfected to overexpress APP695, were treated with either anti-ASC N-terminal antibodies (targeting the pyrin domain) or anti-ASC C-terminal antibodies (targeting the caspase recruitment domain). The study measured cell apoptosis, mitochondrial damage, and Aβ production levels to assess the differential roles of the two ASC domains in Alzheimer's disease pathogenesis. The mechanism of action was explored by examining BACE1 inhibition, as BACE1 is a key enzyme in Aβ production. Results showed that both antibody treatments reduced apoptosis, mitochondrial damage, and Aβ production through BACE1 inhibition.
PRIMARY OUTCOME
Cell apoptosis and Aβ production levels
EXPECTED OUTCOMES
1. The intervention targeting ASC shifts Cell apoptosis and Aβ production levels in the predicted direction relative to the matched control arm.
2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (Cell apoptosis and Aβ production levels) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
- The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
- Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish SH-SY5Y-APP695 cells cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for ASC, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure Cell apoptosis and Aβ production levels together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: This experiment investigated the effects of ASC neutralizing antibodies targeting different domains of the ASC protein on cell apoptosis and amyloid-β (Aβ) production in vitro. SH-SY5Y-APP695 cells, which are human neuroblastoma cells transfected to overexpres
LINKED HYPOTHESES
Source: PMID 41707905 ↗
🧫 Experiment Extras
PATHWAY
ASC-mediated inflammasome pathway, amyloid processing pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.